Figure 3From: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 DiabetesThe observed change in triglyceride concentration over the 28-d treatment period was inversely related to baseline level in the ARA 290 group (panel A; r2 = 0.23; p = 0.022), whereas no relationship was observed for the placebo group (panel B).Back to article page